Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas

Müller, Michael; Frieß, Helmut; Köninger, Jörg; Martín, David; Wente, Moritz N.; Hinz, Ulf; Ceyhan, Güralp O.; Bláha, P; Kleeff, Jörg; Büchler, Markus W.

doi:10.1016/j.amjsurg.2007.02.026

Cited by 90 publications

(74 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research indicated that the mean survival time after DLB was worse for pancreatic cancer patients who had liver metastases (5.8 months) than for those with no metastases (9.7 months) 17 . In the present study, there was no significant difference in the mean survival time between patients with and without liver metastases (5 months vs. 6 months respectively; log rank: p = 0.196).…”

Section: Differences In Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Palliative partial pancreaticoduodenectomy impairs quality of life compared to bypass surgery in patients with advanced adenocarcinoma of the pancreatic head

Walter

Nier

Rose

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

Section: Differences In Survivalmentioning

confidence: 99%

“…Walter et al 8 the main symptoms associated with pancreatic cancer (biliary and gastroduodenal obstruction) and have similar morbidity and mortality rates in specialized centers 10,16,17 .…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Palliative partial pancreaticoduodenectomy impairs quality of life compared to bypass surgery in patients with advanced adenocarcinoma of the pancreatic head

Walter

Nier

Rose

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Human pancreatic cancer BxPC-3 cells (6x10 3 /well/100 µl) were seeded in 96-well culture plates and incubated for 24 h, and then were treated with 0.03125, 0.0625, 0.125, 0.25, 0.5, 1 or 2 µM cucurmosin for 24, 48, 72 h. Control cells were supplemented with 100 µl RPMI-1640 culture medium. After treatment, cells were incubated with MTT 20 µl (0.5 mg/ml) at 37˚C for 4 h, and subsequently moved the culture medium and added dimethyl sulfoxide (DMSO) 200 µl.…”

Section: Methodsmentioning

confidence: 99%

“…Patients diagnosed with pancreatic cancer typically have a poor prognosis. For patients at all stages, the 1-and 5-year survival rates are only 23% and 6%, respectively (2), because a majority of pancreatic cancer at the time of diagnosis is advanced and relative lack of early disease-specific symptoms (3). Since 1997, gemcitabine established its unshakable status as first-line therapy for advanced pancreatic cancer (4).…”

Section: Introductionmentioning

confidence: 99%

Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway

et al. 2011

View full text Add to dashboard Cite

Abstract. Pancreatic cancer remains the fourth most common cause of cancer-related death in the United States. Potent therapeutic strategies are urgently needed for pancreatic cancer. Cucurmosin is a novel type 1 ribosome-inactivating protein (RIP) isolated from the sarcocarp of Cucurbita moschata (pumpkin). Due to its cytotoxicity, cucurmosin can inhibit tumor cell proliferation through induction of apoptosis on tumor cells, but the specific mechanism is still unclear. We explored the function of cucurmosin in BxPC-3 pancreatic cancer cells using multiple cellular and molecular approaches such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, reverse transcription polymerase chain reaction (RT-PCR), Western blotting and transmission electron microscopy for observing typical changes and formation of apoptotic bodies. We found that cucurmosin inhibited the proliferation of BxPC-3 cells in a time-and dose-dependent manner, and increased the cell population in the G0-G1 phase. With increasing concentration of cucurmosin, the expression of EGFR, p-PI3K, Akt, p-Akt, mTOR, p-mTOR, P70S6K-α, p-P70S6K-α, 4E-BP1 and p-4E-BP1 at the protein level was decreased, whereas the expression of p-Bad and caspase-9 was elevated. However, the mRNA expression of EGFR did not change. These findings suggest that cucurmosin can downregulate the expression of EGFR by targeting. Cucurmosin induces the apoptosis of BxPC-3 pancreatic cancer cells via the PI3K/Akt/mTOR signaling pathway.

show abstract

“…It is a fast-developing disease which is difficult to detect and diagnose and often has a poor prognosis. 8,9 Therefore, adjuvant therapy, especially chemotherapy, to improve the quality of life for advanced pancreatic cancer patients is increasingly important. In this study, we investigated the anticancer activity of oridonin on human epithelial-like pancreatic cancer cell line PANC-1, which is used as an in vitro model of nonendocrine pancreatic cancer for tumorigenicity studies.…”

Section: Introductionmentioning

confidence: 99%

Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line

Qi¹,

Zhang²,

Xu³

et al. 2012

IJN

View full text Add to dashboard Cite

Oridonin, a diterpenoid isolated from Rabdosia rubescencs, has been reported to have antitumor effects. However, low solubility has limited its clinical applications. Preparation of drugs in the form of nanosuspensions is an extensively utilized protocol. In this study, we investigated the anticancer activity of oridonin and oridonin nanosuspension on human pancreatic carcinoma PANC-1 cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed to investigate the effect of oridonin on cell growth. Propidium iodide and Hoechst 33342 staining were used to detect morphologic changes. The percentage of apoptosis and cell cycle progression was determined by flow cytometric method staining with propidium iodide. Annexin V-fluorescein isothiocyanate (FITC)/PI staining was used to evaluate cell apoptosis by flow cytometry. Caspase-3 activity was measured by spectrophotometry. The apoptotic and cell cycle protein expression were determined by Western blot analysis. Both oridonin and oridonin nanosuspension induced apoptosis and G 2 /M phase cell cycle arrest, and the latter had a more significant cytotoxic effect. The ratio of Bcl-2/Bax protein expression was decreased and caspase-3 activity was stimulated. The expression of cyclin B1 and p-cdc2 (T161) was suppressed. Our results showed that oridonin nanosuspension was more effective than free oridonin on G 2 /M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line.

show abstract

Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas

Cited by 90 publications

References 39 publications

Palliative partial pancreaticoduodenectomy impairs quality of life compared to bypass surgery in patients with advanced adenocarcinoma of the pancreatic head

Palliative partial pancreaticoduodenectomy impairs quality of life compared to bypass surgery in patients with advanced adenocarcinoma of the pancreatic head

Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway

Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line

Contact Info

Product

Resources

About